MedTrace Logo

Transverse Myelitis Related to SARS-CoV-2 Vaccines

NCT05178264 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 580

Last updated 2022-01-05

No results posted yet for this study

Summary

Few patients receiving SARS-CoV-2 vaccines may experience rare but serious adverse events such as transverse myelitis (TM). Today, data about TM are scarce.

The objective was to investigate reports of TM adverse events related to SARS-CoV-2 vaccines labelled by FDA and EMA, including ChAdOx1nCov-19 (Oxford-AstraZeneca), BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Janssen/Johnson \& Johnson) and using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Conditions

  • Vaccine Adverse Reaction

Interventions

DRUG

SARS-CoV-2 vaccines

All patients treated at least with 1 SARS-CoV-2 vaccine

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2021-12-10
Completion
2021-12-10
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05178264 on ClinicalTrials.gov